2021–2022 Drug Updates in Hematologic Malignancies

During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administrat...

Descripción completa

Detalles Bibliográficos
Autor principal: Tobin, Jenni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184846/
https://www.ncbi.nlm.nih.gov/pubmed/37197730
http://dx.doi.org/10.6004/jadpro.2023.14.3.10
Descripción
Sumario:During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr. Tobin discussed their unique mechanisms of action, administration, and how to monitor for and manage side effects associated with these new therapeutics.

Ejemplares similares